Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersTP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Methylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional MechanismsSequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcomeHow unique is pure erythroid leukaemia? A retrospective analysis of seven cases and review of the literature.Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Treatment of Low-Blast Count AML using Hypomethylating Agents.TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
P2860
Q26743743-B9EE7DE9-70B3-4238-AF24-0C8EC43F936DQ27853319-A7ADBF6E-6D55-4D9E-8C21-74C6260983FCQ35721733-F5D71F71-A257-4D27-91CA-0D7D76696C74Q37074311-60357640-5698-41AB-BD89-2E06115BAAE4Q37327786-E785BDCE-F7BF-4432-92FE-0C73E0645608Q38327599-2608B99B-4102-419B-9402-C529B631BD45Q38540862-FAF49DB5-941B-4AF1-A252-FEDFC7FBF45CQ38739506-467D241D-BD1F-42D3-BD32-295025D46ADAQ38797003-A9209821-DE5D-49D8-8D1B-59B6939E43B4Q38980392-B95FC1AF-915A-4019-9D8A-361416EE138FQ39116272-921643EA-1823-4C60-9BA3-FDF8A714B690Q39429687-DEFAC261-AA6D-48CC-940C-782021B32FA4Q40421122-B63D0AEB-B2D6-40B8-884C-6A70465B1C4DQ40759493-10317F6F-8F2F-4155-B83D-290F5D0FB6D7Q40896172-D55BF0CD-6DAA-45CB-9A01-9E5EA662F995Q41039704-94822245-2C17-4372-8425-5674E965EFADQ49401381-F83E8F77-21DB-4F5A-AFD9-0472B23E4CA7Q52904336-F2CE4149-8791-4B10-998C-492D8F5376DFQ53064376-95313D6D-E1EA-4D5B-BEFB-289E13670D5EQ55364989-B1DB2A36-847F-4C3D-87E4-71D3EF79B630Q55379234-4A422A21-69D7-47AB-B466-897362FD7AA5
P2860
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@en
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@nl
type
label
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@en
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@nl
prefLabel
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@en
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@nl
P2093
P2860
P50
P1433
P1476
Response to azacitidine is ind ...... ondary acute myeloid leukemia.
@en
P2093
Burkhard Schmidt
Catharina Müller-Thomas
Christian Peschel
Christina Huberle
Ina-Christine Rondak
Julie Schanz
Katharina Götze
Marcus Kremer
Martina Rudelius
Rainer Blaser
P2860
P304
P356
10.3324/HAEMATOL.2014.104760
P577
2014-06-27T00:00:00Z